The Road to Precision in Critical Care
- PMID: 38236084
- DOI: 10.1097/CCM.0000000000006213
The Road to Precision in Critical Care
Conflict of interest statement
Dr. Lyons’ institution received funding from the National Institutes of Health (NIH). Dr. Meyer’s institution received funding from the NIH (HL161196, HL168419) and Quantum Leap Healthcare Collaborative; she received funding from EndPoint Health and AstraZeneca. Dr. Maslove has disclosed that he does not have any potential conflicts of interest.
References
-
- Maslove DM, Tang B, Shankar-Hari M, et al.: Redefining critical illness. Nat Med. 2022; 28:1141–1148
-
- Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243:290–293
-
- Zhou Z, Li M: Targeted therapies for cancer. BMC Med. 2022; 20:90
-
- RECOVERY Collaborative Group: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet. 2021; 397:1637–1645
-
- Horby P, Lim WS, Emberson JR, et al.; RECOVERY Collaborative Group: Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021; 384:693–704
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical